This Article Full Text Full Text (PDF) All Versions of this Article: 37/1/156    most recent 01.STR.0000190892.93663.e2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Choi-Kwon, S. Articles by Kim, J. S. Search for Related Content PubMed PubMed Citation Articles by Choi-Kwon, S. Articles by Kim, J. S. Related Collections Behavioral/psychosocial - treatment Other Stroke Treatment - Medical

(Stroke. 2006;37:156.)
© 2006 American Heart Association, Inc.

Original Contributions

Fluoxetine Treatment in Poststroke Depression, Emotional Incontinence, and Anger Proneness

A Double-Blind, Placebo-Controlled Study

Smi Choi-Kwon, PhD, RN; Sung W. Han, RN; Sun U. Kwon, MD; Dong-Wha Kang, MD; Ji M. Choi, RN Jong S. Kim, MD

From the College of Nursing (S.C.-K., J.M.C.), Seoul National University, and Department of Neurology (S.W.H., S.U.K., D.-W.K., J.S.K.), University of Ulsan, Asan Medical Center, Seoul, Korea.

Correspondence to Jong S. Kim, MD, Department of Neurology, Asan Medical Center, Song-Pa PO Box 145, Seoul 138-600, South Korea. E-mail jongskim{at}amc.seoul.kr

Background and Purpose— The efficacy and safety of the selective serotonin reuptake inhibitor fluoxetine have rarely been studied in the treatment of poststroke emotional disturbances.

Methods— Stroke patients (152) who had poststroke depression (PSD), emotional incontinence (PSEI), or anger proneness (PSAP) were studied. PSD was evaluated by Beck Depression Inventory and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, PSEI by Kim’s criteria, and PSAP was assessed by Spielberger Trait Anger Scale. Subjects were randomly given either fluoxetine 20 mg/day (n=76) or placebo (n=76) for 3 months. Follow-up evaluations were done 1, 3, and 6 months after the beginning of the treatment. The primary outcome measurement was the scores of emotional disturbances at each follow-up assessment. The secondary outcome measurements were the percentage changes of the scores and the subjective responses of the patients.

Results— Although patients in the fluoxetine group more often dropped out because of adverse effects, fluoxetine administration was generally safe. Fluoxetine significantly improved PSEI and PSAP, whereas no definitive improvement of PSD was found. Improvement of PSAP was noted even at 3 months after the discontinuation of the treatment.

Conclusions— Fluoxetine is efficacious in the treatment of PSEI and PSAP. Its effect on PSD is not solidly confirmed.

Key Words: depression • emotions • fluoxetine • serotonin • stroke

This article has been cited by other articles:

				W K Tang, Y K Chen, J Y Lu, V C T Mok, Y T Xiang, G S Ungvari, A T Ahuja, and K S Wong Microbleeds and post-stroke emotional lability J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1082 - 1086. [Abstract] [Full Text] [PDF]

				M. Dettling, C. Opgen-Rhein, and I. Anghelescu Escitalopram, Problem-Solving Therapy, and Poststroke Depression JAMA, October 15, 2008; 300(15): 1757 - 1757. [Full Text] [PDF]

				R. G. Robinson, R. E. Jorge, and K. Clarence-Smith Double-Blind Randomized Treatment of Poststroke Depression Using Nefiracetam J Neuropsychiatry Clin Neurosci, May 1, 2008; 20(2): 178 - 184. [Abstract] [Full Text] [PDF]

				Y. Chen, J. J Guo, S. Zhan, and N. C Patel Treatment Effects of Antidepressants in Patients with Post-Stroke Depression: A Meta-Analysis Ann. Pharmacother., December 1, 2006; 40(12): 2115 - 2122. [Abstract] [Full Text] [PDF]